搜索
 >  免疫检查点蛋白>OX40 >Biotinylated Human OX40, Fc Tag, Avi Tag (Avitag™)

Biotinylated Human OX40, Fc Tag, Avi Tag (Avitag™)

分子别名(Synonym)

TNFRSF4,OX40,CD134,OX40L receptor,ACT35,TXGP1L

表达区间及表达系统(Source)

MABSol® Biotinylated Human OX40, Fc Tag, Avi Tag (OX0-H82F7) is expressed from human HEK293 cells. It contains AA Leu 29 - Ala 216 (Accession # NP_003318).

Predicted N-terminus: Leu 29

蛋白结构(Molecular Characterization)

Precision Avi(Leu 29 - Ala 216) NP_003318

This protein carries a human IgG1 Fc fragment at the C-terminus, followed by an Avi tag (Avitag™). The protein has a calculated MW of 48.6 kDa. The protein migrates as 66 kDa on a SDS-PAGE gel under reducing (R) condition due to glycosylation.

标记(Biotinylation)

Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

蛋白标记度(Biotin:Protein Ratio)

The biotin to protein ratio is 0.5-1 as determined by the HABA assay.

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

纯度(Purity)

>90% as determined by SDS-PAGE.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, pH7.5. Normally trehalose is added as protectant before lyophilization.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

No activity loss was observed after storage at:

  1. 4-8°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.
 

电泳(SDS-PAGE)

Biotinylated Human OX40, Fc Tag, Avi Tag (Cat. No. OX0-H82F7) SDS-PAGE gel

Biotinylated Human OX40, Fc Tag, Avi Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.

 

活性(Bioactivity)-ELISA

Biotinylated Human ELISA

Immobilized Human OX40 Ligand, Fc Tag (Cat. No. OXL-H526x) at 5 μg/mL (100 μl/well) can bind Biotinylated Human OX40, Fc Tag, Avi Tag (Cat. No. OX0-H82F7) with a linear range of 0.01-0.3 μg/mL (QC tested).

点击申请Protocol

活性(Bioactivity)-FACS

Biotinylated Human FACS

FACS assay shows that recombinant Biotinylated Human OX40, Fc Tag, Avi Tag (Cat. No. OX0-H82F7) can bind to 293T cell overexpressing human OX40L. The concentration of OX40 is 0.1 μg/ml (Routinely tested).

点击申请Protocol

 

背景(Background)

Tumor necrosis factor receptor superfamily member 4 (TNFRSF4) is also known as ACT35 antigen, OX40L receptor, TAX transcriptionally-activated glycoprotein 1 receptor, CD antigen CD134, OX40. OX40 / TNFRSF4 contains four TNFR-Cys repeats. TNFRSF4 is receptor for TNFSF4 / OX40L / GP34 and can interacts with TRAF2, TRAF3 and TRAF5.

 

专利使用说明(Limited Use License)

The Biotin AviTag technology is covered by U.S. Pat. No: 5,874,239 and includes any and all materials, methods, kits and related derivatives claimed by this patent. The purchase of the Acrobiosystems’s Avitag™ proteins confers to the purchaser the limited right to use the Avitag™ technology for non-commercial, or research use, or for purposes of evaluating the Avitag™ technology.

Commercial use of the Avitag™ technology to manufacture a commercial product, or use of the Avitag™ technology to facilitate or advance research which will be applied to the development of a commercial product requires a license from Avidity, LLC. Examples of Commercial use include, but are not limited to biosensors, diagnostics, therapeutic applications, proximity assays, and drug screening assays.

 

前沿进展

货号/价格

OX0-H82F7-25ug / ¥3500

OX0-H82F7-200ug / ¥13800

文档
联系电话:
400-682-2521(全国)
010-57737274(北京)
021-31604788(上海)
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
techsupport@acrobiosystems.com
OX40靶点信息
英文全称:Tumor necrosis factor receptor superfamily member 4
中文全称:肿瘤坏死因子受体超家族成员4
种类:Homo sapiens
上市药物数量:0详情
临床药物数量:8详情
最高研发阶段:临床二期
查看更多信息

消息提示

请输入您的联系方式,再点击提交!

确定